|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0014582,
umls-concept:C0016360,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0069515,
umls-concept:C0242957,
umls-concept:C0281491,
umls-concept:C0441766,
umls-concept:C0443252,
umls-concept:C0681890,
umls-concept:C1274040,
umls-concept:C1514559,
umls-concept:C1522673
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-9-2
|
|
pubmed:abstractText |
HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1526-8209
|
|
pubmed:author |
pubmed-author:BianAlberto RosaAR,
pubmed-author:BisagniGiancarloG,
pubmed-author:BucciarelliEmilioE,
pubmed-author:CavaliereAntonioA,
pubmed-author:CherubiniRobertaR,
pubmed-author:ColozzaMariantoniettaM,
pubmed-author:De AngelisVerenaV,
pubmed-author:FrassoldatiAntonioA,
pubmed-author:GoriStefaniaS,
pubmed-author:Italian Oncology Group for Clincal Research,
pubmed-author:MazzocchiBrunoB,
pubmed-author:MihailovaZhasminaZ,
pubmed-author:MosconiAnna MariaAM,
pubmed-author:RodinoCarmelinaC,
pubmed-author:SidoniAngeloA,
pubmed-author:TonatoMaurizioM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
253-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16137437-Adult,
pubmed-meshheading:16137437-Antibiotics, Antineoplastic,
pubmed-meshheading:16137437-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16137437-Breast Neoplasms,
pubmed-meshheading:16137437-Chemotherapy, Adjuvant,
pubmed-meshheading:16137437-Cyclophosphamide,
pubmed-meshheading:16137437-Epirubicin,
pubmed-meshheading:16137437-Female,
pubmed-meshheading:16137437-Fluorouracil,
pubmed-meshheading:16137437-Genes, erbB-2,
pubmed-meshheading:16137437-Humans,
pubmed-meshheading:16137437-Mastectomy,
pubmed-meshheading:16137437-Methotrexate,
pubmed-meshheading:16137437-Middle Aged,
pubmed-meshheading:16137437-Neoplasm Staging,
pubmed-meshheading:16137437-Predictive Value of Tests,
pubmed-meshheading:16137437-Prognosis,
pubmed-meshheading:16137437-Randomized Controlled Trials as Topic,
pubmed-meshheading:16137437-Retrospective Studies,
pubmed-meshheading:16137437-Survival Analysis,
pubmed-meshheading:16137437-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
|
|
pubmed:affiliation |
Medical Oncology Division, Azienda Ospedaliera, Sant'Andrea delle Fratte, Perugia, Italy. mariantonietta.colozza@tin.it
|
|
pubmed:publicationType |
Journal Article
|
